Thieme E-Books & E-Journals -
Zurück
Nuklearmedizin 2021; 60(02): 133
DOI: 10.1055/s-0041-1726706
Leuchtturm
Bildgebung und Therapie

Clinical outcomes and patient (pt) profiles in REASSURE: an observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC)

K Miller
1   Charité, Urologie, Berlin
,
C Higano
2   Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
,
F Saad
3   University of Montreal Hospital Center, Montreal, Quebec, Canada
,
O Sartor
4   Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana, USA
,
P Conti
5   Molecular Imaging Center, Keck School of Medicine of USC, Los Angeles, California, USA
,
D George
6   Departments of Medicine and Surgery, Duke Cancer Institute, Duke University, Durham, North Carolina, USA
,
CN Sternberg
7   Weill Cornell Department of Medicine, New York-Presbyterian Hospital, New York, New York, USA
,
N Shore
8   Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA
,
JP Sade
9   Instituto Alexander Fleming, Buenos Aires, Argentina
,
J Bellmunt
10   Dana-Farber Cancer Institute, Boston, Massachusetts, USA
,
M Smith
11   Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
,
C Logothetis
12   MD Anderson Cancer Center, Houston, Texas, USA
,
F Verholen
13   Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA
,
J Kalinovsky
14   Bayer Consumer Care AG, Basel, Switzerland
,
I Bayh
13   Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA
,
B Tombal
15   Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium
› Institutsangaben